121 related articles for article (PubMed ID: 11001327)
1. Control of glycopeptide-resistant enterococci in an oncology unit.
Bradley SJ
Pharmacotherapy; 2000 Sep; 20(9 Pt 2):203S-212S; discussion 224S-228S. PubMed ID: 11001327
[TBL] [Abstract][Full Text] [Related]
2. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage.
Bradley SJ; Wilson AL; Allen MC; Sher HA; Goldstone AH; Scott GM
J Antimicrob Chemother; 1999 Feb; 43(2):261-6. PubMed ID: 11252332
[TBL] [Abstract][Full Text] [Related]
3. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients.
Marie JP; Marjanovic Z; Vekhoff A; Bouvet A; Chast F; Levy V; Baudard M; Legrand O; Rio B; Delmer A; Zittoun R
Support Care Cancer; 1999 Mar; 7(2):89-94. PubMed ID: 10089089
[TBL] [Abstract][Full Text] [Related]
4. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
Hess U; Böhme C; Rey K; Senn HJ
Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of the effects of ceftizoxime, piperacillin, and piperacillin-tazobactam concentrations on antibacterial activity and selection of antibiotic-resistant mutants of Enterobacter cloacae and Bacteroides fragilis in vitro and in vivo in mixed-infection abscesses.
Stearne LE; van Boxtel D; Lemmens N; Goessens WH; Mouton JW; Gyssens IC
Antimicrob Agents Chemother; 2004 May; 48(5):1688-98. PubMed ID: 15105122
[TBL] [Abstract][Full Text] [Related]
6. Piperacillin-tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patients with hematological malignancies: a randomized comparison.
Gorschlüter M; Hahn C; Fixson A; Mey U; Ziske C; Molitor E; Horré R; Sauerbruch T; Marklein G; Schmidt-Wolf IG; Glasmacher A
Support Care Cancer; 2003 Jun; 11(6):362-70. PubMed ID: 12690546
[TBL] [Abstract][Full Text] [Related]
7. Differences in the changes in resistance patterns to third- and fourth-generation cephalosporins and piperacillin/tazobactam among Klebsiella pneumoniae and Escherichia coli clinical isolates following a restriction policy in a Greek tertiary care hospital.
Petrikkos G; Markogiannakis A; Papaparaskevas J; Daikos GL; Stefanakos G; Zissis NP; Avlamis A
Int J Antimicrob Agents; 2007 Jan; 29(1):34-8. PubMed ID: 17189092
[TBL] [Abstract][Full Text] [Related]
8. [Piperacillin-tazobactam in the treatment of severe nosocomial infections].
Venditti M; Cassone M; Falcone M; Pavoni G; Pistella E; Paris A
Recenti Prog Med; 2002 Mar; 93(3):200-11. PubMed ID: 11942173
[TBL] [Abstract][Full Text] [Related]
9. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Marie JP; Vekhoff A; Pico JL; Guy H; Andremont A; Richet H
J Antimicrob Chemother; 1998 Jun; 41 Suppl D():57-64. PubMed ID: 9688452
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective randomized multicenter trial.
Alvarez-Lerma F; Insausti-Ordeñana J; Jordá-Marcos R; Maraví-Poma E; Torres-Martí A; Nava J; Martínez-Pellús A; Palomar M; Barcenilla F;
Intensive Care Med; 2001 Mar; 27(3):493-502. PubMed ID: 11355117
[TBL] [Abstract][Full Text] [Related]
11. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
[TBL] [Abstract][Full Text] [Related]
13. Conjugative resistance to tazobactam plus piperacillin among extended-spectrum beta-lactamase-producing nosocomial Klebsiella pneumoniae.
Akhan S; Coskunkan F; Tansel O; Vahaboglu H
Scand J Infect Dis; 2001; 33(7):512-5. PubMed ID: 11515761
[TBL] [Abstract][Full Text] [Related]
14. Effects of infection control measures on acquisition of five antimicrobial drug-resistant microorganisms in a tetanus intensive care unit in Vietnam.
Schultsz C; Bootsma MC; Loan HT; Nga TT; Thao le TP; Thuy TT; Campbell J; Vien le M; Hoa NT; Hoang NV; Wit F; Chau NV; Farrar J; Bonten MJ; Yen LM
Intensive Care Med; 2013 Apr; 39(4):661-71. PubMed ID: 23306583
[TBL] [Abstract][Full Text] [Related]
15. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial.
Sanz MA; López J; Lahuerta JJ; Rovira M; Batlle M; Pérez C; Vázquez L; Julià A; Palau J; Gutiérrez M; Capote FJ; Ramos F; Benlloch L; Larrea L; Jarque I;
J Antimicrob Chemother; 2002 Jul; 50(1):79-88. PubMed ID: 12096010
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized study comparing cefozopran with piperacillin-tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders.
Sato T; Kobayashi R; Yasuda K; Kaneda M; Iguchi A; Kobayashi K
Pediatr Blood Cancer; 2008 Dec; 51(6):774-7. PubMed ID: 18661495
[TBL] [Abstract][Full Text] [Related]
17. Piperacillin-tazobactam as empiric monotherapy in febrile neutropenic patients with haematological malignancies.
Hazel DL; Graham J; Dickinson JP; Newland AC; Kelsey SM
J Chemother; 1997 Aug; 9(4):267-72. PubMed ID: 9269607
[TBL] [Abstract][Full Text] [Related]
18. Reduction in multiresistant nosocomial infections in neonates following substitution of ceftazidime with piperacillin/tazobactam in empiric antibiotic therapy.
Flidel-Rimon O; Friedman S; Gradstein S; Bardenstein R; Shinwell ES
Acta Paediatr; 2003 Oct; 92(10):1205-7. PubMed ID: 14632339
[TBL] [Abstract][Full Text] [Related]
19. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers.
Stiefel U; Paterson DL; Pultz NJ; Gordon SM; Aron DC; Donskey CJ
Infect Control Hosp Epidemiol; 2004 May; 25(5):380-3. PubMed ID: 15188842
[TBL] [Abstract][Full Text] [Related]
20. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.
Perry CM; Markham A
Drugs; 1999 May; 57(5):805-43. PubMed ID: 10353303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
